Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Sol-Gel Technologies Ltd Is A Dermatology Company. It Is Engaged In Identifying, Developing And Commercializing Branded And Generic Topical Drug Products For The Treatment Of Skin Diseases. The Company'S Product Candidate Pipeline Includes Sgt-610 (Patidegib Gel 2%), A New Chemical Entity Hedgehog Signaling Pathway Blocker, For The Chronic Use And Prevention Of New Bcc In Gorlin Syndrome Patients, And The Topical Drug Candidate Sgt-210 For The Treatment Of Darier Disease And Other Rare Keratosis-Related Indications Such As Pc, Ppk And Olmsted. It Generates The Majority Of Its Revenue From The United States.